Sierra Eye Associates | Reno, NV
Status and phase
Conditions
Treatments
About
This study will assess corneal endothelial cells in patients with neovascular age-related macular degeneration (nAMD) treated with Port Delivery System with ranibizumab (PDS) refilled every 24 weeks (Q24W)
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion Criteria
Ocular Inclusion Criteria
Exclusion Criteria
Prior Ocular Treatment Study Eye
Either Eye
Macular Neovascularization Lesion Characteristics
Study Eye
Either Eye
Concurrent Ocular Conditions Study Eye
Fellow (Non-Study) Eye
• Concurrent PDS implantation
Concurrent Systemic Conditions
Primary purpose
Allocation
Interventional model
Masking
185 participants in 1 patient group
Loading...
Central trial contact
Reference Study ID Number: ML43000 https://forpatients.roche.com/
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal